EB66® Cell line

Advantages The EB66® cell line is one of the best alternatives to chicken eggs and other cell lines. In an independent publication, EB66® was proven to bring significant cost savings due to its rapid population doubling time that can multiply twice as fast as Vero cells. EB66® cells are able to grow in suspension in high-density which further shortens production campaigns and reduces vessel sizes. In addition, the upscalability of EB66® cell growth in stirred tank bioreactors has been demonstrated up to the 4,500 L scale. EB66® is the only duck cell line to be fully documented in a biologics master file with the US Food and Drug Administration. EB66® is also well known by many equivalent authorities across Europe, Latin America, Asia and Africa.

• Susceptible to a broad range of viruses
• Indefinite self-renewal
• Genetically stable
• Scalable
• Growth in suspension shortens production campaigns and reduce vessel sizes
• Serum-free and chemically-defined medias available commercially
• High yielding
• Free of any contaminant organisms

 

---

 

Partnerships

The EB66® cell line is one of the most extensively studied and characterized cell lines available for use in human vaccines development

With 80+ commercial and research partnerships to date worldwide, EB66® has been tested in over 100 pathogens and a broad range of both human and veterinary viruses have successfully grown into it. Since its introduction in 2007, materials derived from the substrate have been administered in numerous human and animal clinical trials. In fact, there are currently 9 approved human and animal commercial vaccines based on EB66®.

 

---

 

Approved vaccines based on EB66® in the U.S., Europe, Japan and Latin America

Human vaccines

• Pandemic H5N1 influenza
• Pandemic influenza

Veterinary vaccines

• Egg Drop Syndrome (2 different vaccines)
• Muscovy Duck Parvovirus
• Inclusion body hepatitis virus
• Infectious bursal disease virus
• Avian Influenza
• Parvovirus

 

---

 

Partners who work with us

 

---

 

publications

• The Avian EB66(R) Cell Line, Application to Vaccines, and Therapeutic Protein Production. Brown SW, Mehtali M. PDA J Pharm Sci Technol. 2010 Sep-Oct;64(5):419-25.
  Culturing a duck ES-derived cell line in single-use bioreactors: a rapid, efficient, and cost-effective vaccine manufacturing system based on suspension culture. Madeline B, Ribaud S, Xenopoulos A, Simler J, Schwamborn K, Léon A. BioProcess Int 2015;13(Suppl. 1):26–33.
• Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial. Schuind A, Segall N, Drame M, Innis BL. J Infect Dis. 2015 Aug 15;212(4):531-41.
• Designing cell lines for viral vaccine production: Where do we stand? Genzel Y. Biotechnol J. 2015 May;10(5):728-40.
• A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03. Naruse T, Fukuda T, Tanabe T, Ichikawa M, Oda Y, Tochihara S, Kimachi K, Kino Y, Ueda K. Vaccine. 2015 Nov 9;33(45):6078-84.
• The EB66 cell line as a valuable cell substrate for MVA-based vaccines production. Léon A, David AL, Madeline B, Guianvarc’h L, Dureau E, Champion-Arnaud P, Hebben M, Huss T, Chatrenet B, Schwamborn K. Vaccine. 2016 Nov 21;34(48):5878-5885.
• Influenza B virus reverse genetic backbones with improved growth properties in the EB66 cell line as basis for vaccine seed virus generation. White KM, Ayllon J, Mena I, Potenski A, Krammer F, García-Sastre A. Vaccine. 2018 Feb 21;36(9):1146-1153.
• Process intensification of EB66 cell cultivations leads to high-yield yellow fever and Zika virus production. Nikolay A, Léon A, Schwamborn K, Genzel Y, Reichl U. Appl Microbiol Biotechnol. 2018 Oct;102(20):8725-8737.
• The duck EB66 cell substrate reveals a novel retrotransposon. Perugi F, Freslon-Evain C, Batard L, Guillet P, Schwamborn K. Biologicals. 2019 Sep;61:22-31.
• Perfusion Control for High Cell Density Cultivation and Viral Vaccine Production. Nikolay A, Bissinger T, Gränicher G, Wu Y, Genzel Y, Reichl U. Methods Mol Biol. 2020;2095:141-168.
• Immunogenicity and protective efficacy of an EB66() cell culture-derived duck Tembusu virus vaccine. Yang Z, Wang J, Wang X, Duan H, He P, Yang G, Liu L, Cheng H, Wang X, Pan J, Zhao J, Yu H, Yang B, Liu Y, Lin J. Avian Pathol. 2020 Oct;49(5):448-456.
• Clinical phase II and III studies of an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66() cell culture platform. Endo M, Tanishima M, Ibaragi K, Hayashida K, Fukuda T, Tanabe T, Naruse T, Kino Y, Ueda K. Influenza Other Respir Viruses. 2020 Sep;14(5):551-563
• Site-specific N-glycosylation analysis of animal cell culture-derived Zika virus proteins. Pralow A, Nikolay A, Leon A, Genzel Y, Rapp E, Reichl U. Sci Rep. 2021 Mar 4;11(1):5147.

 

---

 

Book a meeting with us

Valneva has collaborated with big pharma and biotechs alike, several of today’s leading global veterinary healthcare companies, as well as universities and research institutions. With such diverse experience, we offer tailored deal structures to meet each client’s needs.

We are attending the World Vaccine Congress Europe, the World Vaccine Congress US and the BIO International Convention in the US every year, and would be happy to meet potential partners there.

We would be pleased to learn about your project in an initial discussion to see how EB66® can support you.

To reach us, please call +33 2 28 07 37 10 or complete the form below. We will get in touch shortly.